Skadden, Freshfields and Davis Polk take the lead as blockbuster Pfizer/AstraZeneca deal gears up again Jaishree Kalia28 April 2014Corporate and M&A Skadden, Arps, Slate, Meagher & Flom, Freshfields Bruckhaus Deringer and Davis Polk & Wardwell have all landed lead roles advising Pfizer and AstraZeneca as talks over a potential $100bn merger resurface.Your limit of 1 article in 30 days is up. Please login for full access or subscribe. Corporate users - click here for simple access (no password needed). For more information, please contact [email protected] Related ContentMore in this categoryTrading Places: Paul Weiss and Latham tap senior government talentSeal of approval: the LB100 firms with the strongest client recommendationsRevolving Doors: Three leave Taylor Wessing after merger vote, while Gibson Dunn taps Freshfields for APAC rebuildPaul Hastings hires London M&A partner from Slaughter and MayLatham returns to Wachtell for two-partner finance and M&A hirePaul Hastings in London M&A push with hire of Cooley Singapore founding partnerRevolving doors: Simpson Thacher, Latham, Sidley lead New Year London movesFive partners vie to succeed Hoyland as Simmons managing partner‘Seize every opportunity’ – Paul Hastings partner Reena Gogna on City law, Suits and poetry